By Fineline Cube 
Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that its CIGB-814 immunomodulator has commenced a Phase 1 clinical trial for the treatment of rheumatoid arthritis. The trial recently completed the enrollment of its first subject.
Drug Profile
CIGB-814 is designed to achieve an appropriate immune response. It effectively clears pathogens while avoiding excessive immune reactions that could damage the body’s tissues. Preclinical data show that CIGB-814 regulates CD4+ T cells, particularly inducing regulatory effects on Treg cells. It also reduces levels of inflammatory cytokines like IL-17 and TNF-α, thereby decreasing inflammation or the expression of inflammatory effector cells.-Fineline Info & Tech